AAD’s DataDerm™ 2017 QCDR Measures
As a 2017 Qualified Clinical Data Registry (QCDR), Eligible Clinicians will be able to report the measures listed below for MIPS credit through the AAD’s DataDerm™. Please contact the American Academy of Dermatology if you are interested in using these copyrighted measures outside of DataDerm.AAD ID / Measure Name / Description / Steward / Type of Measure / National Quality Strategy Domain
07 / Psoriasis: Assessment of Psoriasis Disease Activity / Percentage of patients with plaque psoriasis who have disease activity assessed by using one of the listed measures or validated instruments/ tools* at least once during the measurement period.
* Assessment and classification of disease activity using standardized descriptive measures or tools resulting in a numeric score or composite index: Scales and instruments are examples and cut‐points can differ by scale. Standardized descriptive or numeric scales and/or composite indexes include: Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Physician’s Global Assessment (PGA), Dermatology Life Quality Index (DLQI). / AAD / Process / Effective Clinical Care
08 / Psoriasis: Screening for Psoriatic Arthritis / Percentage of patients with diagnosis of psoriasis who are screened for psoriatic arthritis at least once during the measurement period. / AAD / Process / Person & Caregiver-Centered Experience & Outcomes
10 / Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients / The percentage of immune‐competent patients with pathologically‐proven primary superficial basal cell carcinoma (BCC) lesions on the trunk (chest, back, abdomen) who are treated with Mohs surgery. / AAD / Process / Efficiency and Cost Reduction
11 / Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk / The percentage of immune‐competent patients with pathologically‐proven primary squamous carcinoma in situ (SCCis) lesions of any size on the trunk (chest, back, abdomen) or keratoacanthoma type squamous cell carcinoma (SCC‐KA) lesions 1 cm or smaller on the trunk (chest, back, abdomen) who are treated with Mohs surgery. / AAD / Process / Efficiency and Cost Reduction
12 / Biopsy: Reporting Time – Clinician to Patient / Percentage of patients with skin biopsy specimens with a diagnosis of cutaneous basal or squamous cell carcinoma (including in situ disease) who are notified of their final biopsy pathology findings within less than or equal to 14 days from the time the biopsy was performed. / AAD / Process / Efficiency and Cost Reduction
©American Academy of Dermatology/Association. All rights reserved.
The American Academy of Dermatology and the American Academy of Dermatology
Association (collectively AAD/A) own all right, title, and interest in the quality measures
presented on these web pages. These quality measures are provided solely for the benefit of
AAD/A and its members for the purposes specified herein and for other AAD/A purposes. They
may not be used by other parties except with prior written approval of the AAD/A.
American Academy of Dermatology June 19, 2017